<DOC>
	<DOCNO>NCT01531972</DOCNO>
	<brief_summary>This open-label study investigate relationship SEP-228432 SEP-228431 ( active metabolite SEP-228432 ) plasma concentration , SERT occupancy , DAT occupancy , measure SPECT imaging .</brief_summary>
	<brief_title>A Phase 1 , Open-Label , Single-photon Emission Computed Tomography ( SPECT ) Study Evaluate Serotonin Dopamine Transporter Occupancy After Multiple Dose Administration SEP-228432 Achieve Steady State Healthy Subjects</brief_title>
	<detailed_description>This open-label study investigate relationship SEP-228432 SEP-228431 ( active metabolite SEP-228432 ) plasma concentration , SERT occupancy , DAT occupancy , measure SPECT image use [ 123I ] -2β-carbomethoxy-3β- ( 4-iodophenyl ) tropane ( [ 123I ] β -CIT ) . Up 3 sequential cohort 8 subject multiple dose administration SEP-228432 . The target dose first cohort 200 mg . Dose selection remain cohort base preliminary review available relevant data prior dose cohort ( ) .</detailed_description>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>Subject must give write informed consent prior participation study . Subject must willing able comply study procedure visit schedule must able follow verbal write instruction . Male female subject 1850 year age ( inclusive ) time sign consent . Subject must judge condition general good health ( define absence clinically relevant abnormality determine investigator ) , base screen medical psychiatric history , physical examination , neurological examination , vital sign , clinical laboratory value ( hematology , chemistry , urinalysis ) , 12lead ECG . Subject , female , must negative serum pregnancy test screening . All subject must instruct agree avoid pregnancy study must use acceptable method birth control : An oral contraceptive , intrauterine device ( IUD ) , implantable contraceptive , transdermal injectable contraceptive least 30 day prior screen continue use throughout study 30 day follow study participation . Barrier method contraception , eg , condom and/or diaphragm spermicide participate study . Abstinence . Subject must willing stay within residential facility require period must willing attend 3 additional outpatient visit . Subject 's body mass index ( BMI ) must least 16 kg/m2 32 kg/m2 . Subject must willing refrain strenuous activity course study . Subject poor venous access would cause difficulty collect blood sample . Subject history exposure radiation ≥ 15 mSv/year ( eg , occupational radiation therapy ) within previous year . Subject participate investigational drug study receive investigational drug within 30 day prior sign inform consent ( exception previous SPECT image study investigational drug administer radiotracer ) , currently participate another clinical trial . Subject clinically significant unstable medical condition clinically significant chronic disease . Subject evidence history clinically significant hematological ( include deep vein thrombosis ) bleeding disorder , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( except untreated , asymptomatic allergy time dose ) . Subject history severe multiple allergic reaction medication . Subject history hospitalization within 45 day prior sign inform consent . Subject positive test Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus ( HIV ) 1 , HIV2 antibody , history positive result . Subject presence history medically diagnose , clinically significant psychiatric disorder ( include mental retardation ) . Female subject pregnant lactating . Subject history cancer ( exception : basal cell carcinoma remission ) . Subject experience significant blood loss ( ≥ 473 mL ) donate blood within 60 day prior sign informed consent ; donate plasma within 72 hour prior sign informed consent ; intend donate plasma blood undergo elective surgery study participation within 60 day last study visit . Subject history substance abuse drug abuse within 12 month prior sign informed consent positive drug screen Visit 1 . Subject history tobacco dependency use tobacco nicotine within 30 day prior sign inform consent ( include pipe , cigar , patch , chew tobacco , spray , inhaler , gum ) positive urine cotinine test Visit 1 . Subject history regular alcohol consumption exceed 7 drinks/week woman 14 drinks/week men ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) within 6 month prior sign inform consent . Subject consume 180 mg caffeine per day ( 3 cup coffee equivalent caffeinated beverage ) . Subject disorder history condition may interfere drug absorption , distribution , metabolism , excretion clinically significant abnormality hepatic renal system , history malabsorption , previous gastrointestinal surgery ( eg , cholecystectomy , vagotomy , bowel resection , surgical procedure ) could affect drug absorption metabolism , gastrointestinal motility , pH . Subject clinically significant abnormal 12lead ECG may jeopardize subject 's ability complete study Screening 12lead ECG demonstrate one following : heart rate &gt; 100 beat per minute ( bpm ) , QRS &gt; 120 m , QTc &gt; 450 m , PR &gt; 220 m determine investigator use core laboratory ECG interpretation report . Subject use prescription nonprescription drug , vitamin , dietary herbal supplement within 14 day prior sign inform consent . Enzymeinducing herbal supplement ( eg , Metabolife™ ) must discontinue least 30 day prior sign inform consent . Subject previously receive study drug study . Subject staff member relative staff member . Subject opinion investigator , unsuitable way participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Single-photon Emission Computed Tomography</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Tomography</keyword>
</DOC>